Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
SPDR® S&P® Biotech ETF
ETF
XBI
Payout Change
Pending
Price as of:
$96.24
+1.94
+2.06%
primary theme
Health Care Sector Equity
XBI (ETF)
SPDR® S&P® Biotech ETF
Payout Change
Pending
Price as of:
$96.24
+1.94
+2.06%
primary theme
Health Care Sector Equity
XBI (ETF)
SPDR® S&P® Biotech ETF
Payout Change
Pending
Price as of:
$96.24
+1.94
+2.06%
primary theme
Health Care Sector Equity
Name
As of 11/22/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
7.9%
1 yr return
32.4%
3 Yr Avg Return
-6.9%
5 Yr Avg Return
1.9%
Net Assets
$7.55 B
Holdings in Top 10
33.1%
52 WEEK LOW AND HIGH
$94.3
$73.03
$104.18
Expenses
OPERATING FEES
Expense Ratio 0.35%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 74.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 11/22/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
XBI - Profile
Distributions
- YTD Total Return 7.9%
- 3 Yr Annualized Total Return -6.9%
- 5 Yr Annualized Total Return 1.9%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio 0.18%
- Dividend Yield 0.1%
- Dividend Distribution Frequency Quarterly
Fund Details
-
Legal NameSPDR® S&P® Biotech ETF
-
Fund Family NameState Street Global Advisors - advised funds
-
Inception DateFeb 06, 2006
-
Shares Outstanding83200000
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerMichael Feehily
Fund Description
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the “Index”), the Fund employs a sampling strategy, which means that the Fund is not required to purchase all of the securities represented in the Index. Instead, the Fund may purchase a subset of the securities in the Index in an effort to hold a portfolio of securities with generally the same risk and return characteristics of the Index. The quantity of holdings in the Fund will be based on a number of factors, including asset size of the Fund. Based on its analysis of these factors, SSGA Funds Management, Inc. (“SSGA FM” or the “Adviser”), the investment adviser to the Fund, either may invest the Fund's assets in a subset of securities in the Index or may invest the Fund's assets in substantially all of the securities represented in the Index in approximately the same proportions as the Index, as determined by the Adviser to be in the best interest of the Fund in pursuing its objective.Under normal market conditions, the Fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, in seeking to track the Index, the Fund may invest in equity securities that are not included in the Index. The Fund may also invest in cash and cash equivalents or money market instruments (including money market funds advised by the Adviser) for cash management purposes. In seeking to track the Index, the Fund's assets may be concentrated in an industry or group of industries, but only to the extent that the Index concentrates in a particular industry or group of industries. Futures contracts (a type of derivative instrument) may be used by the Fund in seeking performance that corresponds to the Index and in managing cash flows.The Index represents the biotechnology segment of the S&P Total Market Index (“S&P TMI”). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is one of twenty-one (21) of the S&P Select Industry Indices (the “Select Industry Indices”), each designed to measure the performance of a narrow sub-industry or group of sub-industries determined based on the Global Industry Classification Standard (“GICS”). Membership in the Select Industry Indices is based on the GICS classification, as well as liquidity and market cap requirements. Companies in the Select Industry Indices are classified according to GICS which determines classifications primarily based on revenues; however, earnings and market perception are also considered. The Index consists of the S&P TMI constituents belonging to the Biotechnology sub-industry that satisfy the following criteria: (i) have a float-adjusted market capitalization greater than or equal to $500 million with a float-adjusted liquidity ratio (defined by dollar value traded over the previous 12 months divided by the float-adjusted market capitalization as of the index rebalancing reference date) greater than or equal to 90% or have a float-adjusted market capitalization greater than or equal to $400 million with a float-adjusted liquidity ratio (as defined above) greater than or equal to 150%; and (ii) are U.S. based companies. To evaluate liquidity, the dollar value traded for initial public offerings or spin-offs that do not have 12 months of trading history is annualized. If there are fewer than 35 stocks, stocks from the Life Sciences Tools & Services sub-industry that meet the market capitalization and liquidity thresholds are included in order of their float-adjusted market capitalization from largest to smallest. If there continues to be fewer than 22 stocks, the market capitalization threshold may be relaxed to ensure that there are at least 22 stocks in the Index as of the rebalancing effective date. Existing Index constituents are removed at the quarterly rebalancing effective date if either their float-adjusted market capitalization falls below $300 million or their float-adjusted liquidity ratio falls below 50%. The market capitalization threshold and the liquidity threshold are each reviewed from time to time based on market conditions. The Index is modified equal weighted. The Index rebalances and reconstitutes quarterly on the third Friday of the quarter ending month and a secondary reweighting is performed on the third to last business day of the quarter ending month. The reference date for additions and deletions is after the close of the last trading date of the previous month. The S&P TMI tracks all eligible U.S. common equities listed on the NYSE, NYSE Arca, NYSE American, NASDAQ Global Select Market, NASDAQ Global Market, NASDAQ Capital Market, Cboe BZX, Cboe BYX, Cboe EDGA, or Cboe EDGX exchanges. As of July 31, 2024, the Index comprised 136 stocks.The Index is sponsored by S&P Dow Jones Indices LLC (the “Index Provider”), which is not affiliated with the Fund or the Adviser. The Index Provider determines the composition of the Index, relative weightings of the securities in the Index and publishes information regarding the market value of the Index.
Read More
XBI - Performance
Return Ranking - Trailing
| Period | XBI Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 7.9% | -27.4% | 20.8% | 44.03% |
| 1 Yr | 32.4% | -14.9% | 52.4% | 6.29% |
| 3 Yr | -6.9%* | -28.3% | 10.0% | 89.47% |
| 5 Yr | 1.9%* | -7.8% | 12.3% | 89.04% |
| 10 Yr | 5.4%* | 0.3% | 13.0% | 75.68% |
* Annualized
Return Ranking - Calendar
| Period | XBI Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 7.6% | -12.6% | 19.0% | 16.35% |
| 2022 | -25.9% | -53.9% | 3.2% | 90.79% |
| 2021 | -20.5% | -39.6% | 24.2% | 86.18% |
| 2020 | 48.0% | -13.6% | 178.2% | 6.71% |
| 2019 | 32.6% | 3.8% | 63.8% | 9.02% |
Total Return Ranking - Trailing
| Period | XBI Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 7.9% | -27.4% | 20.8% | 44.03% |
| 1 Yr | 32.4% | -14.9% | 52.4% | 6.29% |
| 3 Yr | -6.9%* | -28.3% | 10.0% | 89.47% |
| 5 Yr | 1.9%* | -7.8% | 12.3% | 89.04% |
| 10 Yr | 5.4%* | 0.3% | 13.0% | 75.68% |
* Annualized
Total Return Ranking - Calendar
| Period | XBI Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 7.6% | -12.6% | 19.0% | 22.64% |
| 2022 | -25.9% | -53.9% | 3.7% | 92.76% |
| 2021 | -20.5% | -33.9% | 26.0% | 98.68% |
| 2020 | 48.3% | -0.7% | 180.6% | 6.71% |
| 2019 | 32.6% | 4.6% | 63.8% | 20.30% |
XBI - Holdings
Concentration Analysis
| XBI | Category Low | Category High | XBI % Rank | |
|---|---|---|---|---|
| Net Assets | 7.55 B | 6.66 M | 45.7 B | 10.06% |
| Number of Holdings | 143 | 25 | 430 | 9.43% |
| Net Assets in Top 10 | 2.36 B | 2.12 M | 22.1 B | 15.09% |
| Weighting of Top 10 | 33.14% | 18.4% | 79.7% | 89.31% |
Top 10 Holdings
- State Street Navigator Securities Lending Portfolio II 7.46%
- Sarepta Therapeutics Inc 3.31%
- United Therapeutics Corp 2.98%
- Alnylam Pharmaceuticals Inc 2.86%
- Gilead Sciences Inc 2.84%
- Amgen Inc 2.82%
- AbbVie Inc 2.74%
- Regeneron Pharmaceuticals Inc 2.73%
- Exact Sciences Corp 2.72%
- Biogen Inc 2.69%
Asset Allocation
| Weighting | Return Low | Return High | XBI % Rank | |
|---|---|---|---|---|
| Stocks | 99.94% | 87.34% | 106.13% | 7.55% |
| Cash | 7.50% | 0.00% | 33.01% | 14.47% |
| Other | 0.03% | -22.99% | 23.24% | 28.30% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 96.86% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 95.45% |
| Bonds | 0.00% | 0.00% | 12.39% | 96.23% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | XBI % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 46.10% |
| Utilities | 0.00% | 0.00% | 0.00% | 95.45% |
| Technology | 0.00% | 0.00% | 22.69% | 95.45% |
| Real Estate | 0.00% | 0.00% | 5.89% | 96.10% |
| Industrials | 0.00% | 0.00% | 7.02% | 96.10% |
| Financial Services | 0.00% | 0.00% | 1.60% | 97.40% |
| Energy | 0.00% | 0.00% | 0.00% | 95.45% |
| Communication Services | 0.00% | 0.00% | 9.11% | 95.45% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 96.75% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 96.10% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 96.75% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | XBI % Rank | |
|---|---|---|---|---|
| US | 99.94% | 66.06% | 104.41% | 6.29% |
| Non US | 0.00% | 0.00% | 28.87% | 97.48% |
XBI - Expenses
Operational Fees
| XBI Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.35% | 0.08% | 4.48% | 95.60% |
| Management Fee | 0.35% | 0.03% | 1.25% | 7.55% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| XBI Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| XBI Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| XBI Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 74.00% | 0.00% | 238.00% | 88.15% |
XBI - Distributions
Dividend Yield Analysis
| XBI | Category Low | Category High | XBI % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.06% | 0.00% | 6.24% | 36.48% |
Dividend Distribution Analysis
| XBI | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Quarterly | Annual | Quarterly | Annual |
Net Income Ratio Analysis
| XBI | Category Low | Category High | XBI % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 0.18% | -2.54% | 1.85% | 26.97% |
Capital Gain Distribution Analysis
| XBI | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Sep 23, 2024 | $0.015 | OrdinaryDividend |
| Jun 24, 2024 | $0.115 | OrdinaryDividend |
| Dec 18, 2023 | $0.014 | OrdinaryDividend |
| Jun 20, 2023 | $0.003 | OrdinaryDividend |
| Mar 22, 2021 | $0.040 | OrdinaryDividend |
| Dec 21, 2020 | $0.176 | OrdinaryDividend |
| Sep 21, 2020 | $0.089 | OrdinaryDividend |
| Jun 22, 2020 | $0.017 | OrdinaryDividend |
| Dec 20, 2019 | $0.001 | OrdinaryDividend |
| Sep 20, 2019 | $0.003 | OrdinaryDividend |
| Dec 21, 2018 | $0.012 | OrdinaryDividend |
| Sep 21, 2018 | $0.073 | OrdinaryDividend |
| Jun 15, 2018 | $0.058 | OrdinaryDividend |
| Mar 16, 2018 | $0.059 | OrdinaryDividend |
| Dec 15, 2017 | $0.035 | OrdinaryDividend |
| Sep 15, 2017 | $0.037 | OrdinaryDividend |
| Jun 16, 2017 | $0.110 | OrdinaryDividend |
| Mar 17, 2017 | $0.020 | OrdinaryDividend |
| Dec 16, 2016 | $0.018 | OrdinaryDividend |
| Sep 16, 2016 | $0.031 | OrdinaryDividend |
| Jun 17, 2016 | $0.045 | OrdinaryDividend |
| Mar 18, 2016 | $0.058 | OrdinaryDividend |
| Dec 18, 2015 | $0.149 | OrdinaryDividend |
| Sep 18, 2015 | $0.050 | OrdinaryDividend |
| Jun 19, 2015 | $0.146 | OrdinaryDividend |
| Mar 20, 2015 | $0.082 | OrdinaryDividend |
| Dec 19, 2014 | $0.164 | OrdinaryDividend |
| Sep 19, 2014 | $0.188 | OrdinaryDividend |
| Jun 20, 2014 | $0.205 | OrdinaryDividend |
| Mar 21, 2014 | $0.111 | OrdinaryDividend |
| Dec 20, 2013 | $0.013 | OrdinaryDividend |
| Sep 20, 2013 | $0.029 | OrdinaryDividend |
| Jun 21, 2013 | $0.017 | OrdinaryDividend |
| Mar 15, 2013 | $0.015 | OrdinaryDividend |
| Dec 21, 2012 | $0.066 | OrdinaryDividend |
| Dec 18, 2009 | $0.001 | OrdinaryDividend |
| Mar 20, 2009 | $0.050 | OrdinaryDividend |
| Dec 19, 2008 | $0.002 | OrdinaryDividend |
| Jun 20, 2008 | $0.224 | OrdinaryDividend |
| Mar 20, 2008 | $0.009 | OrdinaryDividend |
| Dec 21, 2007 | $0.007 | OrdinaryDividend |
XBI - Fund Manager Analysis
Managers
Michael Feehily
Start Date
Tenure
Tenure Rank
Oct 31, 2011
10.59
10.6%
Mr. Feehily, CFA, is a Managing Director of SSGA and the Adviser and Co-Head of Passive Equity Strategies in North America in the Global Equity Beta Solutions Group. In this capacity, Mr. Feehily has oversight of the North American Passive Equity teams in Boston and Montreal. In addition, Mr. Feehily is a member of the Senior Management Group. Mr. Feehily rejoined SSgA in 2010 after spending the previous four years at State Street Global Markets LLC where he helped to build the Exposure Solutions business.
Karl Schneider
Start Date
Tenure
Tenure Rank
Oct 31, 2014
7.59
7.6%
Karl Schneider, CAIA, is a Vice President of SSGA and SSGA FM, and Head of U.S. Equity Strategies for GEBS, where in addition to overseeing the management of the U.S. equity index strategies, he also serves as a portfolio manager for a number of the group's passive equity portfolios. Previously within GEBS, he served as a portfolio manager and product specialist for synthetic beta strategies, including commodities, buy/write, and hedge fund replication. Prior to joining GEBS, Mr. Schneider worked as a portfolio manager in SSGA's Currency Management Group, managing both active currency selection and traditional passive hedging overlay portfolios. He joined SSGA in 1996. Mr. Schneider holds a BS in finance and investments from Babson College and an MS in finance from Boston College. He has earned the Chartered Alternative Investment Analyst designation. Mr. Schneider is a member of the CAIA Association.
Raymond Donofrio
Start Date
Tenure
Tenure Rank
Jan 03, 2017
5.41
5.4%
Raymond Donofrio is a Vice President within SSGA and a Senior Portfolio Manager in the Global Equity Beta Solutions Group. Ray is currently responsible for managing various equity index funds, with both domestic and international strategies. Prior to his current role, Ray was an Analyst for SSGA's Strategy and Research group within the Global ETF Group. He began his career as an associate within the Investment Operations team at SSGA. He supported the Portfolio Managers of the Global Equity Beta Solutions team, mainly focusing on international strategies.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |
